Arbeitsgruppe Neuroendokrine Tumoren/Karzinoide - Studien

AIO-assoziierte Studie
  zur Studie

AIO-NET-0217/ass: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first line chemotherapy (AveNEC study)
  --- in Rekrutierung ---

AIO-assoziierte Studie für weitere Zentren offen   zur Studie

AIO-NET-0117/ass: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNet study)
  --- in Vorbereitung---

AIO-assoziierte Studie   www.clinicaltrials.gov zur Studie 

AIO-NET-0417/ass: A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somato-statin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) (COMPETE Study)
  --- in Vorbereitung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-NET-0112: Safety and Tolerability of Everolimus as second–line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 (WHO 2010) and neuroendocrine tumor G3 – an investigator inititated Phase II study (EVINEC)
  --- in Rekrutierung ---

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-NET-0215/ass: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)
  --- in Rekrutierung ---

AIO-assoziierte Studie
www.clinicaltrials.gov
zur Studie

AIO-NET-0116/ass: A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. placebo plus BSC for tumour control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumours. (SPINET-Trial)
  --- in Rekrutierung ---

AIO-assoziierte Studie
www.clinicaltrials.gov
zur Studie

AIO-NET-0216/ass: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days. (CLARINET FORTE-Trial)
  --- in Rekrutierung ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 11.01.2018